NanoPacific Holdings, Inc. (NPH) announces the acquisition of an
exclusive license from University of California at Los Angeles (UCLA)
for a suite of supramolecular nanoparticle technologies. Under the terms
of the agreement between NPH and UCLA, NPH will have an exclusive
worldwide license of a system composed of a ternary mixture of modular
components that self-assemble into supramolecular nanoparticles. The
technology enables the synthesis of new-generation nanoparticles with a
high degree of size and morphological control, as well as tunable
surface charge and chemistry. These properties enable the production of
biodegradable nanoparticles that display improved physiological
stability, longer blood retention times, low acute toxicity and low
immunogenicity. The tunable surface properties allow several types of
functionality to be easily incorporated for imaging (optical, magnetic
and nuclear), targeting and controlled delivery of cargo. This is
synergistic with NPH’s materials science platform.
“We are pleased to have licensed this technology. This further
illustrates our ability and commitment to selectively add important
technologies to our platform. This technology, developed by Dr. Tseng
along with several other collaborators at UCLA has profound implications
for drug delivery, gene transfection centering on siRNA, and companion
diagnostics,” stated Joseph A. Boystak, Chairman & Co-CEO.
“This technology should facilitate our ability to collaborate with a
variety of corporate partners, research institutions and other academic
researchers,” said Michael Flesch, Vice Chairman & Co-CEO.
“I am pleased that my interaction and involvement with NPH will
accelerate the development of the supramolecular nanoparticle systems
toward applications in biology and medicine,” said Dr. Tseng, Associate
Professor, Molecular and Medical Pharmacology at UCLA.
NanoPacific Holdings, Inc.